Xylanase variants and polynucleotides encoding same
AssigneeNovozymes A/S
InventorsBrian R. Scott, Mark David Wogulis, Sven Pedersen, James Lavigne
Life of this patent
Estimating the term…
Loading patent…
AssigneeNovozymes A/S
InventorsBrian R. Scott, Mark David Wogulis, Sven Pedersen, James Lavigne
Estimating the term…
The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of SEQ ID NO: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
A xylanase variant, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO:
Dependencies are inferred from the claim text.